Basel Medical Group Ltd. has reaffirmed its strong financial position amidst recent volatility in its share price. CEO Dr. Darren Chhoa assured stakeholders that the fundamentals of the company remain robust, with subsidiaries securing sizable contracts and the acquisition growth strategy on track. The company believes the share price decline does not reflect its intrinsic value or the progress made in operational execution and capital management.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.